{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wang LL"],"funding":["NCI NIH HHS"],"pagination":["57-63"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4647535"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["113(1)"],"pubmed_abstract":["<h4>Background</h4>MYCN amplification with subsequent MYCN protein overexpression is a powerful indicator of poor prognosis of neuroblastoma patients. Little is known regarding the prognostic significance of the homologous MYC protein expression in neuroblastoma.<h4>Methods</h4>Immunostaining for MYCN and MYC protein was performed on 357 undifferentiated/poorly differentiated neuroblastomas. Results were analysed with other prognostic markers.<h4>Results</h4>Sixty-seven (19%) tumours were MYCN(+), 38 (11%) were MYC(+), and one(0.3%) had both proteins(+). MYCN(+) tumours and MYC(+) tumours were more likely diagnosed in children>18months with stage4-disease. MYCN(+) tumours were associated with amplified MYCN, Unfavourable Histology (UH), and High-MKI (Mitosis-Karyorrhexis Index). MYC(+) tum"],"journal":["British journal of cancer"],"pubmed_title":["Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study."],"pmcid":["PMC4647535"],"funding_grant_id":["U10 CA098543","R01CA127571","P01 CA081403","P01CA081403","R01 CA127571","U10 CA180886","U10 CA180899","U10CA98413","U10CA98543","U10 CA098413"],"pubmed_authors":["Maris JM","Asgharzadeh S","Look AT","London WB","Ikegaki N","Naranjo A","Hogarty MD","Park JR","Cohn SL","Teshiba R","Seeger RC","Shimada H","Tang XX","Gastier-Foster JM","Wang LL"],"additional_accession":[]},"is_claimable":false,"name":"Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study.","description":"<h4>Background</h4>MYCN amplification with subsequent MYCN protein overexpression is a powerful indicator of poor prognosis of neuroblastoma patients. Little is known regarding the prognostic significance of the homologous MYC protein expression in neuroblastoma.<h4>Methods</h4>Immunostaining for MYCN and MYC protein was performed on 357 undifferentiated/poorly differentiated neuroblastomas. Results were analysed with other prognostic markers.<h4>Results</h4>Sixty-seven (19%) tumours were MYCN(+), 38 (11%) were MYC(+), and one(0.3%) had both proteins(+). MYCN(+) tumours and MYC(+) tumours were more likely diagnosed in children>18months with stage4-disease. MYCN(+) tumours were associated with amplified MYCN, Unfavourable Histology (UH), and High-MKI (Mitosis-Karyorrhexis Index). MYC(+) tum","dates":{"release":"2015-01-01T00:00:00Z","publication":"2015 Jun","modification":"2025-04-22T15:10:46.857Z","creation":"2019-03-27T02:02:04Z"},"accession":"S-EPMC4647535","cross_references":{"pubmed":["26035700"],"doi":["10.1038/bjc.2015.188"]}}